Department of Hematology and Transfusion Medicine, Carlo Poma Hospital, Mantova, Italy.
Eur J Haematol. 2021 Aug;107(2):173-180. doi: 10.1111/ejh.13665. Epub 2021 Jun 9.
Very rare cases of thrombosis associated with thrombocytopenia have occurred following the vaccination with AstraZeneca COVID-19 vaccine. The aim of this concise review is to summarize the current knowledge on the epidemiologic and pathogenic mechanisms of this syndrome named vaccine-associated immune thrombosis and thrombocytopenia (VITT). A practical patient management section will also be dealt with using information available from national and international scientific societies as well as expert panels. A literature search on the VITT syndrome was carried out in PubMed using appropriate MeSH headings. Overall, 40 VITT cases have been reported. Continuous pharmacovigilance monitoring is needed to collect more data on the real incidence and the pathogenesis of VITT syndrome. Such information will also help us to optimize the management this rare but often clinically severe thrombotic condition associated with COVID-19 vaccination.
非常罕见的情况下，血栓形成与血小板减少症发生后，接种阿斯利康 COVID-19 疫苗。本简明综述的目的是总结目前的知识，流行病学和发病机制的这种综合征命名疫苗相关免疫性血栓形成和血小板减少症（VITT）。一个实用的病人管理部分也将涉及使用从国家和国际科学协会以及专家小组提供的信息。在 PubMed 上使用适当的 MeSH 标题对 VITT 综合征进行了文献检索。总的来说，已经报告了 40 例 VITT 病例。需要持续进行药物警戒监测，以收集更多关于 VITT 综合征真实发病率和发病机制的数据。这些信息也将有助于我们优化对与 COVID-19 疫苗接种相关的这种罕见但通常临床严重的血栓形成疾病的管理。
